Inclusion Criteria:

- Biopsy proven squamous cell carcinoma of the head and neck, including the oral
cavity, oropharynx, hypopharynx, or larynx, but not including primary tumors of the
nasopharynx, sinuses, or salivary glands.

- Locally advanced, Stage III to IVB disease, and a candidate for primary therapy using
chemotherapy and radiation therapy with curative intent.

- Patients with a diagnosis of 'unknown primary' will be eligible if chemoradiotherapy
is the primary modality of treatment

- No previous chemotherapy, radiation, or surgery for their diagnosis of head and neck
cancer

- ECOG performance status
- Women of child-bearing potential must have a negative pregnancy test within 30 hours
before initiation of study drug dosing. Female subjects of reproductive potential
must agree to avoid pregnancy throughout the study and for up to 3 months following
discontinuation of study drug. Male subjects must agree to avoid conceiving a child
throughout the study and for up to 3 months following discontinuation of study drug;

- Hemoglobin >/= 8.0 gm/dL

- Absolute neutrophil count >/= 1500

- Platelet count >/= 100,000

- GFR > 50 mL/min calculated by the Cockcroft-Gault equation

- Total bilirubin Gilbert's syndrome

- AST and ALT
- No other current malignancy, other than basal cell skin cancer, squamous cell skin
cancer, in situ cervical cancer, ductal or lobular in situ of the breast. Patients
with other malignancies are eligible if they have been continuously disease-free for
>/= 3 years prior to screening for this protocol.

- Age of 18 or older

- Ability and willingness to give informed consent

- Subjects must in the opinion of the Investigator be capable of complying with this
protocol.

Exclusion Criteria:

- Acute treatment for an infection or other serious medical illness within 14 days
prior to study entry

- Major surgery within 3 weeks prior to study entry

- Known hypersensitivity to cisplatin or cetuximab

- Patients who have any severe or uncontrolled medical conditions or other conditions
that could affect their participation in this study, including: unstable angina,
serious uncontrolled cardiac arrhythmia, active acute or uncontrolled infectious
disorder, or myocardial infarction
- Female patients who are pregnant or breast feeding, or adults who are of reproductive
potential and are unwilling to refrain from conceiving a child during study
treatment.

- Patients unwilling to comply with the protocol, or provide informed consent

- Psychiatric illness that would limit compliance with study requirements